Scientific Advisory Committee

Made up of 14 prestigious PKD physicians and scientists, the Scientific Advisory Committee (SAC) oversees our research and medical programs aimed at discovering and delivering treatments for PKD. The SAC meets throughout the year to discuss relevant medical issues, provide guidance to our staff and review and approve research applications for grants and fellowships in the field of PKD science. All our materials and publications are approved by SAC members, who possess the highest level of experience and knowledge in PKD clinical and scientific work.


Michal Mrug, M.D. – Chair

University of Alabama at Birmingham – Department of Medicine/Division of Nephrology

Dr. Mrug’s clinical interests center on evaluation and management of adult patients with PKD. His current research focuses on the identification of specific genes and molecular pathways that modulate PKD severity and progression. He is continuing his collaboration with Dr. Guay-Woodford to identify non-PKD genes that contribute to phenotypic variability in PKD.

Vishal Patel, M.D. – Vice Chair

University of Texas Southwestern Medical Center

Vishal Patel, M.D., is an Assistant Professor of Medicine at the University of Texas Southwestern Medical Center in Dallas, Texas. He obtained his medical degree in India and then completed his internal medicine residency training at the McGraw Medical Center of Northwestern University in Chicago, and a clinical nephrology fellowship and a basic science fellowship sponsored by the National Institutes of Health at the University of Texas Southwestern Medical Center. Dr. Patel has received numerous awards for academic achievement during medical school and a career development award from the NIH. He was also named a ‘rising star’ in Nephrology by Texas Monthly magazine.

Dr. Patel runs a pre-clinical polycystic kidney disease research laboratory at UT Southwestern. His research is focused on understanding the role of microRNAs in PKD progression and developing microRNA-based drugs for PKD. His laboratory is funded by grants from the NIH and the PKD foundation. In addition to research, Dr. Patel also sees patients at Parkland Hospital in Dallas, Texas. He is planning to launch a new multidisciplinary clinic in the coming months with the goal of providing comprehensive clinical care for PKD patients at UT Southwestern.

Terry Watnick

Terry Watnick, M.D. – Past Chair

The University of Maryland

Dr. Terry Watnick, M.D., is an associate professor in the Division of Nephrology at the University of Maryland School of Medicine, where she established an inherited renal disease clinic. She has also been an investigator in several multicenter clinical trials recruiting patients with ADPKD, including TEMPO. She moved to the University of Maryland School of Medicine in 2012 where she leads the Baltimore Polycystic Kidney Disease Research and Clinical Core Center. She currently serves as the Scientific Advisory Committee (SAC) Chair for the PKD Foundation’s Board of Trustees. Dr. Watnick received her medical degree from The Yale School of Medicine and completed her internal medicine training at Yale-New Haven Hospital. She then moved to the Johns Hopkins Hospital where she received clinical training in Nephrology. She also completed a research fellowship that was focused on the genetics of autosomal dominant polycystic kidney disease. Dr. Watnick subsequently joined the faculty at the Johns Hopkins School of Medicine where she rose through the ranks to associate professor. During this time she continued to develop her clinical and research interests in inherited kidney diseases.


Alessandra Boletta, Ph.D.

San Raffaele Scientific Institute – Milan, Italy

The main interest of Dr. Boletta’s laboratory is to understand the normal function of PC-1 protein in ADPKD and to identify potential new targets for therapy in PKD. In a recent study, her laboratory also described a defect at the level of glucose metabolism in PKD.  She received a PKD Foundation grant for a continuation of this work. One additional interest is in understanding the mechanism which leads to renal epithelial transformation in a subset of cystic kidney diseases, such as Tuberous Sclerosis Complex, which are characterized by the presence of cystadenomas and carcinomas in addition to cysts.

Neera Dahl, M.D.

Yale University, School of Medicine

Dr. Neera Dahl is currently a clinician-educator and an Associate Professor at Yale University, School of Medicine, Section of Nephrology. She completed an MD and PhD from Tufts University School of Medicine, and then residency and fellowship at the Beth Israel Deaconess Medical Center, in Boston, MA. She has been at Yale since 2007. She has been instrumental in developing the Yale Inherited Kidney disease clinical program, and is the principal investigator for several ongoing clinical trials in ADPKD. She maintains an active ADPKD registry and is involved in research exploring the role of inflammation and fibrosis in the progression of ADPKD. She is the director of the Yale Nephrology Clinical Trials Program.

Iain Drummond, Ph.D.

Massachusetts General Hospital, Harvard Medical School

Iain Drummond received his Ph.D. from the University of California Berkeley for work on ionic signaling and the Drosophila heat shock response. His postdoctoral work at Northwestern University Medical School and the University of Chicago focused on gene regulation in Dictyostelium and the Wilms tumor suppressor in human cells. Dr. Drummond is currently an Associate Professor in Medicine and Genetics at Harvard Medical School, Massachusetts General Hospital. His lab established the zebrafish as a genetic system for discovering mechanisms of kidney development and disease.  His work has revealed new genes required for cilia function in organogenesis and in human Primary Ciliary Dyskinesia, established collective cell migration as an essential element of nephron morphogenesis, discovered new pathways underlying nephrotic syndrome, revealed new cellular mechanisms linked to Polycystin gene functions, and developed the zebrafish pronephros as an in vivo system to evaluate pathogenicity of candidate human disease gene sequence polymorphisms. His lab is now exploring mechanisms of kidney regeneration from adult kidney stem cells.

Mitchell Friedman, Ph.D.

Takeda Pharmaceuticals

Mitchell Friedman, Ph.D. has extensive experience in the drug development industry. He has demonstrated technical, scientific and project management leadership through filing numerous drug/device applications in both the United States and internationally. He served as a US representative to the International Standards Organization (ISO). He has led teams across a diverse range of activities including drug safety software evaluation and implementation and post-market surveillance of drugs and devices; drug development teams across a wide range of therapeutic areas; medical device development teams; formulation of development teams; clinical teams; software validation teams. In his current role as Global Lead for Drug Development, Drug Safety Research, and Evaluation at Takeda, he is responsible for strategies on new drug development and data interpretation.

Dr. Friedman holds a B. S. in biology from the University of Kansas at Lawrence and a Ph.D. in pharmacology/toxicology from the University of Texas at Austin.

Berenice Gitomer, Ph.D.

University of Colorado Anschutz Medical Center

Berenice Gitomer, Ph.D., is a Research Professor of Medicine in the Division of Renal Diseases and Hypertension and an Associate Director of the Polycystic Kidney Disease Research Group at the University of Colorado Anschutz Medical Campus. She joined the Renal Division at the University of Colorado as a full-time faculty member in 2003 to study the genetics of autosomal dominant polycystic kidney disease (ADPKD). She obtained her doctoral degree from Trinity College, Dublin, Ireland before coming to the U.S. to complete a postdoctoral fellowship at the National Institutes of Health. She subsequently joined the faculty at the University of Texas Southwestern Medical Center to study the genetics of kidney stone disease. Dr. Gitomer’s research focuses on the identification of factors that affect the severity and progression of ADPKD, with the goal of identifying new therapeutic targets to slow disease progression.

Erum Hartung, M.D.

Children’s Hospital of Philadelphia

Erum Aftab Hartung, M.D., MTR, is a pediatric nephrologist at the Children’s Hospital of Philadelphia (CHOP). Her research interests include autosomal recessive polycystic kidney disease (ARPKD), development of imaging biomarkers of kidney and liver disease, and neurocognitive outcomes in children with chronic kidney disease. She currently serves as chair of the Research Committee of the American Society of Pediatric Nephrology, and is the Associate Program Director for the pediatric nephrology fellowship at CHOP. Dr. Hartung’s research is funded by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) and the University of Pennsylvania (Penn). Dr. Hartung is on the faculty of the Perelman School of Medicine at Penn as Assistant Professor of Pediatrics. She lives in Swarthmore, PA with her husband and two children.

Jinghua Hu, Ph.D.

Mayo Clinic

Jinghua Hu, Ph.D., is an Associate Professor of Biochemistry and Molecular Biology in the Department of Biochemistry and Molecular Biology and an Association Professor of Medicine in the Division of Nephrology and Hypertension at Mayo Clinic. Dr. Hu received his Ph.D. from Chinese Academy of Science in 2001. He completed his postdoctoral training with Dr. Maureen M. Barr at the University of Wisconsin-Madison and was recruited as an Assistant Professor of Medicine and BMB in 2007.

Dr. Hu’s research systematically explores cilia-related human diseases, or collectively termed ciliopathies, by using various disease models from the inexpensive and efficient nematode C. elegans, to cultured mammalian cells and genetically-engineered rodent models. His lab has developed numerous ciliopathy models of ciliopathies, including ADPKD and other syndromic renal disorders such as nephronophthisis, Bardet-Biedl syndrome, Meckel-Gruber syndrome, and Joubert syndrome, with the goal of understanding the pathogenesis of cystogenesis and testing the potential for diagnostic/therapeutic purposes. Dr. Hu administered numerous extramural funding, and presently holds two R01 grants from NIDDK, and Co-PI on another two R01s with his Mayo colleagues.  Dr. Hu also serves as a Co-director of the Model Organism Core in NIH-funded P30 Mayo Translational PKD Center.

Frederic Rahbari-Oskoui, M.D.

Emory University School of Medicine

Dr. Frederic Rahbari-Oskoui is an Associate Professor of Medicine and the Director of the Cystic and Inherited Kidney Diseases Clinic at Emory University School of Medicine in Atlanta, GA. He obtained his medical degree from the University of Bordeaux in France and completed his first residency training in Internal Medicine at the same university.

Dr. Rahbari completed a second internal medicine residency program at St. Vincent’s Medical Center-Columbia University in 2002 and enrolled in a 3-year academic track fellowship in Nephrology and cystic kidney diseases under Dr. Arlene Chapman’s mentorship at Emory University. He joined the Faculty at Emory University in 2006 as an instructor in medicine and was promoted to the rank of Assistant Professor of Medicine in 2008 and Associate Professor of Medicine in 2014.

Dr. Rahbari’s research expertise is in the fields of renal cystic diseases and particularly polycystic kidney disease. He has been an investigator in several landmark trials in ADPKD including: HALT-PKD, TEMPO, REPRISE, and the CRISP observational cohort. His other areas of interest are hypertension, imaging studies of the kidneys and acute kidney injury.

Dr. Rahbari has coauthored more than 40 original articles, review articles, UpToDate chapters, communication letters, and about 40 abstracts and poster presentations at local and national meetings.

Dr. Rahbari firmly supports the fantastic effort of the PKD Foundation and has been a regular participant in the Walk for PKD, fundraising and patient information sessions in GA, NC, and TN.

Richard Sandford, M.D., Ph.D., FRCP

University of Cambridge, Cambridge Institute of Medical Research

Dr. Sandford qualified in London in 1985 and trained in nephrology in Leicester, London, and Cambridge before developing a special interest in renal genetic diseases in Cambridge after completing his Ph.D. in 1995.

Since then he has specialized in renal genetics and is part of the Cambridge Renal Genetics and Tubular Disorders Clinic in The Addenbrookes Treatment Centre. Many individuals and families living with ADPKD are seen in this clinic which combined nephrology, genetics, urology and clinical biochemistry in a multidisciplinary setting.

His research interests include the clinical epidemiology of ADPKD, genetic testing, and methods of predicting disease progression.

Darren Wallace, Ph.D.

University of Kansas Medical Center

Dr. Wallace is an Associate Professor in the Department of Medicine and the Kidney Institute at the University of Kansas Medical Center. He received his Ph.D. from the Department of Molecular and Integrative Physiology at KUMC in 1998 and joined the faculty of the Department of Medicine in 2002. Dr. Wallace’s research is funded by an R01 grant from the National Institutes of Health (NIDDK). He is the Director of the PKD Research Biomaterials and Cellular Models Core funded by the PKD Foundation. Additional research support is derived from private foundations and biotechnology companies. Dr. Wallace is also a member of the Scientific Advisory Committee for the PKD Foundation.

Robert H. Weiss, M.D.

University of California Davis, Sacramento VA Medical Center

Dr. Robert H. Weiss is a clinician/scientist nephrologist and cell biologist and is Professor of Medicine, Emeritus, at UC Davis and Chief of Nephrology at the Sacramento VA Medical Center. His training was all at several campuses of the University of California. His clinical and research interests are broad and include vascular and hereditary renal disease as well as kidney cancer. He was among the first to characterize the role of the cyclin kinase inhibitors in cancer as well as to utilize metabolomics to search for biomarkers and therapeutic targets in kidney cancer and PKD.